Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Revenue (2016 - 2025)

Historic Revenue for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $56.3 million.

  • Vanda Pharmaceuticals' Revenue rose 1806.26% to $56.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.1 million, marking a year-over-year increase of 1111.61%. This contributed to the annual value of $198.8 million for FY2024, which is 318.31% up from last year.
  • Vanda Pharmaceuticals' Revenue amounted to $56.3 million in Q3 2025, which was up 1806.26% from $52.6 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' Revenue's 5-year high stood at $70.1 million during Q3 2021, with a 5-year trough of $38.8 million in Q3 2023.
  • Over the past 5 years, Vanda Pharmaceuticals' median Revenue value was $56.3 million (recorded in 2025), while the average stood at $56.5 million.
  • In the last 5 years, Vanda Pharmaceuticals' Revenue tumbled by 4057.53% in 2023 and then soared by 2276.44% in 2024.
  • Vanda Pharmaceuticals' Revenue (Quarter) stood at $68.0 million in 2021, then decreased by 5.2% to $64.5 million in 2022, then fell by 29.79% to $45.3 million in 2023, then rose by 17.48% to $53.2 million in 2024, then increased by 5.78% to $56.3 million in 2025.
  • Its Revenue was $56.3 million in Q3 2025, compared to $52.6 million in Q2 2025 and $50.0 million in Q1 2025.